statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	583
SG - Singapore	229
IT - Italia	212
VN - Vietnam	137
CN - Cina	116
HK - Hong Kong	64
BD - Bangladesh	60
BR - Brasile	60
IE - Irlanda	43
DE - Germania	40
FR - Francia	30
IN - India	26
FI - Finlandia	24
NL - Olanda	24
GB - Regno Unito	18
ZA - Sudafrica	18
AT - Austria	16
KR - Corea	16
CA - Canada	15
RU - Federazione Russa	15
SE - Svezia	11
TW - Taiwan	10
MX - Messico	9
PL - Polonia	9
ES - Italia	8
TR - Turchia	7
AR - Argentina	5
ID - Indonesia	5
UA - Ucraina	5
TH - Thailandia	4
VE - Venezuela	4
CI - Costa d'Avorio	3
EC - Ecuador	3
IQ - Iraq	3
UZ - Uzbekistan	3
AE - Emirati Arabi Uniti	2
BE - Belgio	2
BO - Bolivia	2
CL - Cile	2
CO - Colombia	2
CR - Costa Rica	2
CZ - Repubblica Ceca	2
DZ - Algeria	2
JP - Giappone	2
KZ - Kazakistan	2
MA - Marocco	2
MD - Moldavia	2
RO - Romania	2
SA - Arabia Saudita	2
SK - Slovacchia (Repubblica Slovacca)	2
SY - Repubblica araba siriana	2
TN - Tunisia	2
AU - Australia	1
BH - Bahrain	1
DO - Repubblica Dominicana	1
EE - Estonia	1
ET - Etiopia	1
HR - Croazia	1
HU - Ungheria	1
IR - Iran	1
JO - Giordania	1
LB - Libano	1
LT - Lituania	1
MR - Mauritania	1
NO - Norvegia	1
PA - Panama	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PY - Paraguay	1
SN - Senegal	1
UY - Uruguay	1
Totale	1.889

Nome	#
Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays	327
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro	228
The Impact of Possible Misuses Conditions on in Vitro Performance of NEXThaler in Comparison with Ellipta Inhaler	191
Development of a nasal spray based on cyclodextrin/hydrophobically-modified hydroxypropyl-methyl cellulose for the prevention of viral respiratory infections	168
Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2	153
Unveiling tablet structural changes: A micro computed tomography analysis of aqueous coating effects	153
Respicell(TM): An innovative dissolution apparatus for inhaled products	150
No-shaking and shake-fire delays affect respirable dose for suspension but not solution pMDIs (vol 631, 122478, 2023)	123
Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections	121
Fluorescence-enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray device	115
Drugs as contaminants of emerging concern: preventive approaches beyond detection, regulatory aspects and remediation	102
Long-acting inhaled medicines: Present and future	74
CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases	8
Totale	1.913

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	11	0	0	0	0	6	0	0	0	0	0	1	4
2022/2023	68	2	3	1	4	1	2	11	9	20	8	4	3
2023/2024	109	6	2	2	6	9	9	30	6	3	3	14	19
2024/2025	436	9	11	9	49	35	36	42	32	45	37	46	85
2025/2026	1.289	75	80	130	109	140	61	136	69	162	122	153	52
Totale													1.913